Immune checkpoint blockade (ICB) with programmed cell death (ligand)-1 [PD-(L)1] inhibitors is a promising approach to HPV-driven malignancy based on clinical experience in head and neck squamous cell carcinoma (HNSCC) (14) and cervical cancer (15). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.